Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acalabrutinib for GVHD Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia

Next Previous
X
Search
Trial Profile

Acalabrutinib for GVHD Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 11 Mar 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acalabrutinib (Primary) ; Methotrexate; Tacrolimus
  • Indications Graft-versus-host disease
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 20 Feb 2022 Planned initiation date changed from 1 Jan 2022 to 1 Mar 2022.
    • 20 Feb 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 03 Nov 2021 Planned End Date changed from 1 Oct 2029 to 1 Jan 2030.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top